Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases
Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2022
SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient has been dosed in the AFFINITY Study, a phase 2 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A receptor, in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
“Initiation of the phase 2 AFFINITY Study is an important step in evaluating atrasentan across multiple proteinuric glomerular diseases for which there are currently limited treatment options,” said Alan Glicklich, M.D., chief medical officer of Chinook. “Atrasentan’s proteinuria-lowering, anti-fibrotic and anti-inflammatory properties have the potential to provide therapeutic benefit in a variety of chronic kidney diseases. Data generated in the AFFINITY Study will help inform the development strategy for atrasentan in these additional indications in parallel to our phase 3 ALIGN Study in IgA nephropathy.”
About the AFFINITY Study
The primary efficacy endpoint of the AFFINITY Study is the effect on proteinuria as measured by urine protein to creatinine ratio (UPCR) in patients with IgAN, FSGS and Alport syndrome and the change in albuminuria as measured by urine albumin to creatinine (UACR) in patients with DKD, from baseline to 12 weeks. Chinook expects to report data from initial cohorts of patients in the AFFINITY Study during 2022.
About Chinook Therapeutics, Inc.
Cautionary Note on Forward-Looking Statements
Keynote Presentation by Google
Keynote Presentation by Zoom